Amgen today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback